id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-1656-0007,FDA,FDA-2013-E-1656,Notice of Determination from U.S. Patent and Trademark Office to the FDA CDER,Other,Letter(s),2016-12-20T05:00:00Z,2016,12,2016-12-20T05:00:00Z,,2016-12-20T15:14:00Z,,0,0,0900006482429cb7
FDA-2013-E-1656-0006,FDA,FDA-2013-E-1656,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-01-07T05:00:00Z,2016,1,2016-01-07T05:00:00Z,,2016-01-07T19:02:07Z,,0,0,0900006481df4591
FDA-2013-E-1656-0005,FDA,FDA-2013-E-1656,"Determination of Regulatory Review Period for Purposes of Patent 
Extension; XELJANZ",Notice,Determinations,2015-06-12T04:00:00Z,2015,6,2015-06-12T04:00:00Z,2015-12-10T04:59:59Z,2016-01-12T19:18:52Z,2015-14433,0,0,0900006481b30329
FDA-2013-E-1656-0004,FDA,FDA-2013-E-1656,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-03-31T04:00:00Z,2015,3,2015-03-31T04:00:00Z,,2015-03-31T18:44:07Z,,0,0,0900006481a7e840
FDA-2013-E-1656-0003,FDA,FDA-2013-E-1656,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-03-26T04:00:00Z,2014,3,2014-03-26T04:00:00Z,,2014-03-26T16:47:25Z,,0,0,0900006481683025
FDA-2013-E-1656-0002,FDA,FDA-2013-E-1656,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-12-18T05:00:00Z,2013,12,2013-12-18T05:00:00Z,,2013-12-18T20:59:39Z,,0,0,09000064814ca381
FDA-2013-E-1656-0001,FDA,FDA-2013-E-1656,Pfizer Inc. -  Patent Term Application,Other,Application,2013-12-18T05:00:00Z,2013,12,2013-12-18T05:00:00Z,,2013-12-18T21:06:55Z,,0,0,09000064814ca380